Study Title: A First-in-Human, Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Orr, Brian, at orrb@musc.edu.Study Coordinator, Drake, Abigail, at abd300@musc.edu.Trial opened at the following institutions: Medical University of South Carolina